Amazon.com, Inc. (NASDAQ:AMZN) raised 0.68% during the previous trading session as the firm held price to earnings ratio of 179.92. Amazon (AMZN) reported that it has quite the reputation for thinking outside the box and for going the extra mile to give consumers incentives to sign up for or renew Amazon Prime subscriptions. Those two traits make a recent Wall Street Journal report about plans for a sports package aimed at Prime subs particularly intriguing.
However, regardless of how innovative and bold Amazon’s effort proves to be, its success depends on accords with major sports leagues that have already licensed much of their best content to TV networks. As a result, the service may simply be another tool to keep Prime subs happy than a major threat to pay-TV — at least in the U.S. …596 more words left in this article. To read them, just click below and try Real Money.
Can investors take a chance on buying AMZN this week? Find Out Here
Stocks of China New Borun Corporation (NYSE:BORN) appeared in active trade move, plunged -1.56% to trade at $1.39 in last session with shares volume of 34643. China New Borun Corporation (NYSE:BORN) reported that its unaudited financial results for the third quarter ended September 30, 2016.
Mr. Jinmiao Wang, Chairman and Chief Executive Officer of Borun, commented on the results, “Driven by solid demand from the baijiu industry, we were able to deliver record sales volume of edible alcohol and exceeded our previous income guidance for the third quarter of 2016. However, during the quarter, record-low corn prices caused a sharp over-supply of edible alcohol, which pressured pricing and profitability. As we enter a new harvest season this November, corn prices have stabilized, and we anticipate our profitability will gradually rebound.” To taking a short look on firm’s performance of margin, it showed a positive 4.80% in the net profit margin and in addition to its operating margin, which remained 7.40%.
Will China New Borun Corporation retains its glamour following this report? Read Considerable Report Here
Allergan plc (NYSE:AGN) keeps its position active in street, shares closed at $188.84 with decreases of -1.20%. Allergan plc (NYSE:AGN) reported that it has completed the acquisition of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical firm focused on the development of improved treatments for neurodegenerative disorders comprising Alzheimer’s disease (AD), Allergan takeoverd Chase for an upfront payment of $125 million and additional potential regulatory and sales milestone payments related to Chase’s lead compound, CPC-201, and certain backup compounds.
“Alzheimer’s disease is a neurodegenerative disease that represents a major and growing global public health problem, for which very few agreed treatment options are accessible , and the societal cost is measured in hundreds of billions of dollars, so the need for improved treatment choices is paramount,” stated David Nicholson, Chief Research & Development Officer, Allergan. The firm has yearly sales growth for the past five year of 33.40%. While past twelve months price to sales ratio recorded as 4.96 and price to cash ratio remained 2.70.
Should investors bet on Allergan plc following this recent trend? Read Considerable Report Here